Mirati Showcases New KRAS Drug Data In Colorectal Cancer At ESMO

Mirati Therapeutics Inc MRTX announced results from the 600mg BID dose cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib in heavily pretreated colorectal cancer patients harboring a KRASG12C mutation.
Results showed that adagrasib alone and with cetuximab demonstrated significant clinical activity and broad disease control in these patients.
The data were presented at the European Society for Medical Oncology Congress (ESMO21) 2021.
As of May 25, the response rate in the 45 evaluable patients who received adagrasib as monotherapy stood at 22%, including one unconfirmed partial response (PR) and a disease control rate (DCR) of 87%.
The median duration of response was 4.2 months, with the median progression-free survival (PFS) was 5.6 months.
Mirati also shared an update on patients who have received adagrasib in combination with Eli Lilly And Co's LLY Erbitux (cetuximab).
The response rate in the 28 evaluable patients who received the combination was 43%, including two people with unconfirmed partial responses and a disease control rate of 100% at a median seven-month check-in.
After the July 9 data cutoff, follow-up scans confirmed one response, but the other patient progressed.
There were no deaths reported in either arm of the study, and the combination arm outperformed the solo drug arm in terms of Grade 3/4 side effects with rates of 16% and 30%, respectively.
Price Action: MRTX stock is down 3.19% at $168.50 during the premarket session on the last check Monday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga